Status:
UNKNOWN
NASH and Coronary Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Institute of Cardiometabolism and Nutrition, France
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Although the clinical relationship between NAFLD/NASH and cardiovascular (CV) risk is now well established, there is very little awareness of the hepatic disease and the way it may contribute to incre...
Detailed Description
Because of shared metabolic risk factors and pathogenic pathways (insulin resistance, chronic low grade inflammation, atherogenic dyslipidemia) non-alcoholic fatty liver disease is frequently associat...
Eligibility Criteria
Inclusion
- Adult patients (\>18 years old) that undergo coronary angiography for suspected CAD for: acute coronary syndrome (ACS) with ST-elevation ACS (STE-ACS) or non-ST elevation (NSTE-ACS) with or without troponin elevation OR suspicion of stable coronary artery disease after stress imaging techniques and/or symptoms of angina.
- Patients with one or more of traditional cardiovascular risk factors.
Exclusion
- Patients unable to sign the informed consent
- Morbidly obese patients (BMI \> 40kg/m2)
- Excessive alcohol consumption of more than 50 g/day
- Patients with known other causes of chronic liver disease (viral hepatitis, autoimmune, hemochromatosis...)
- Active neoplastic pathology
- Pregnant or breastfeeding women
- Protected adults
Key Trial Info
Start Date :
April 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 19 2024
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT03819283
Start Date
April 19 2019
End Date
July 19 2024
Last Update
September 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pitié Salpêtrière Hospital
Paris, France, 75013